(Citric acid + lactic acid + potassium bitartrate) is a Small Molecule owned by Evofem Biosciences, and is involved in 6 clinical trials, which were completed.

Phexxi (Amphora) gel lines the vaginal canal and helps maintain the vagina's natural acidic pH level, when sperm is introduced. By maintaining the pH level, Phexxi creates a hostile environment for sperm, inhibiting their ability to migrate to the cervix, and thus prevents pregnancy.

The revenue for (Citric acid + lactic acid + potassium bitartrate) is expected to reach a total of $2.9bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the (Citric acid + lactic acid + potassium bitartrate) NPV Report.

(Citric acid + lactic acid + potassium bitartrate) is currently owned by Evofem Biosciences.

(Citric acid + lactic acid + potassium bitartrate) Overview

Citric acid, Lactic acid and Potassium bitartrate (Phexxi) is a fixed dose combination act as non-hormonal contraception. It is formulated as gel for vaginal route of administration. Phexxi is indicated for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception. Phexxi is not effective for the prevention of pregnancy when administered after intercourse.

Amphora is under development as a female contraception, prevention of bacterial vaginosis. The therapeutic candidate is administered through vaginal route. It is a non-hormonal vaginal contraceptive gel that consists of L-lactic Acid, citric acid, and potassium bitartrate. It was also under development for genital herpes, chlamydia trachomatis infection, Neisseria gonorrhoeae infections  and HIV-1 infections.

Evofem Biosciences Overview

Evofem Biosciences (Evofem) carries out the development and commercialization of reproductive and contraceptive care products for women. The company’s pipeline products include phexxi, a hormone-free contraceptive vaginal gel; and EVO200 vaginal gel, to treat recurrent bacterial vaginosis (BV). It uses proprietary multipurpose prevention technology (MPT) vaginal gel candidate for multiple indications which include human immunodeficiency virus (HIV) prevention; contraception; prevention of urogenital transmission of chlamydia trachomatis infection and Neisseria gonorrhea infection in women. Evofem sells its product under the brand name Phexxi. The company markets its product across the globe through partnerships and licensing agreements. Evofem is headquartered in San Diego, California, US.

The company reported revenues of (US Dollars) US$8.2 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$0.5 million in FY2020. The operating loss of the company was US$166.8 million in FY2021, compared to an operating loss of US$103.6 million in FY2020. The net loss of the company was US$205.2 million in FY2021, compared to a net loss of US$142.3 million in FY2020. The company reported revenues of US$6 million for the second quarter ended June 2022, an increase of 41.9% over the previous quarter.

Quick View – (Citric acid + lactic acid + potassium bitartrate)

Report Segments
  • Innovator (Non-NME)
Drug Name
  • (Citric acid + lactic acid + potassium bitartrate)
Administration Pathway
  • Vaginal
Therapeutic Areas
  • Infectious Disease
  • Women’s Health
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.